Survodutide
Survodutide is a 29-amino-acid peptide developed for weight loss and treatment of MASH.
We have not published an audit on Survodutide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Survodutide acts as a dual GLP-1 and glucagon receptor agonist, targeting both receptors simultaneously. [Source: Peptide Dosing Protocols]
Survodutide is a once-weekly injection that activates two receptors at the same time, one that reduces appetite (GLP-1) and one that may help the body burn more calories and reduce liver fat (glucagon), which is why it is being studied for both weight loss and a serious fatty liver disease called MASH.
Reported side effects
The most common side effects of survodutide in trials were nausea, vomiting, diarrhea, and constipation, which were worst during the dose-escalation phase and often improved once the dose leveled off.
Who should avoid it
People who are pregnant or breastfeeding, have a personal or family history of medullary thyroid cancer or MEN 2, have had pancreatitis, have severe gut disease, take insulin or sulfonylureas, are children or teenagers, or have known peptide allergies should avoid survodutide outside of a formal clinical trial.
What gets monitored
Weight, waist size, blood pressure, heart rate, fasting glucose, HbA1c for people with diabetes, and basic liver labs are suggested for monitoring. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Survodutide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 4.8 mg once weekly · Low: 0.6 mg once weekly · High: 4.8 mg once weekly | once weekly76 weeks · null | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: null. Survodutide is administered at a standard dose of 4.8 mg once weekly. |
- once weekly76 weeks · null
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: null. Survodutide is administered at a standard dose of 4.8 mg once weekly.
- 1.0 to 2.0 mL per vial
Common questions
What is Survodutide?
Survodutide is a 29-amino-acid peptide developed by Boehringer Ingelheim with Zealand Pharma, acting on both the GLP-1 receptor and the glucagon receptor.
Is Survodutide FDA-approved?
No, as of June 2026, Survodutide is investigational and not FDA-approved for any human use.
How much weight did people lose with Survodutide?
In the Phase 3 SYNCHRONIZE-1 trial, adults lost an average of 16.6% of body weight at 76 weeks.
How is Survodutide dosed in clinical trials?
The Phase 2 obesity trial used once-weekly doses of 0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg.
Can I buy Survodutide?
Survodutide is not available by prescription in the United States as of June 2026.
How does Survodutide compare to Retatrutide?
Survodutide targets GLP-1 and glucagon, while Retatrutide targets GLP-1, GIP, and glucagon.
How does Survodutide compare to Tirzepatide?
Tirzepatide is GLP-1 plus GIP, while Survodutide is GLP-1 plus glucagon.
What are the main Survodutide side effects?
The most common side effects are nausea, vomiting, diarrhea, and constipation.
Sources
- 01Boehringer Ingelheim. Results from Phase III SYNCHRONIZE-1 obesity trial (press release, April 28, 2026). Boehringer Ingelheim (2026)
- 02Le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology (2024)
- 03Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine (2024)
- 04Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA1c and bodyweight reductions with a dual glucagon/GLP-1 receptor agonist, survodutide, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2024)
- 05Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism (2022)
- 06Authors et al. Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials. PMC (peer-reviewed meta-analysis) (2025)
- 07Mikhail N, Wali S. Survodutide, a promising agent with novel mechanism of action for treatment of obesity and type 2 diabetes. Journal of Endocrinology and Disorders (2024)
- 08ClinicalTrials.gov. A Study to Test How Well Different Doses of BI 456906 Help People With Overweight or Obesity Lose Weight (NCT04667377, Phase 2). ClinicalTrials.gov (2024)
- 09ClinicalTrials.gov. A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Lose Weight (SYNCHRONIZE-1, NCT06066529). ClinicalTrials.gov (2026)
- 10U.S. Food and Drug Administration. Drugs@FDA: search for survodutide approval status (no approved product as of June 2026). FDA.gov (2026)
The reference sections above are imported from our compound knowledge base, which classes the evidence for Survodutide as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.
Peptide bioregulator referenced for pineal support.